For example, BRCA1 promoter methylation indicates PARPi resistance of triple-negative breast cancer cells, which makes germline BRCA1 mutations the most reliable biomarkers in predicting tumor response to the PARPi-based therapies [126]. Here, BRCA1 is linked to neoplasm.